In this section
@article{Abitbol:2024:10.1080/21645515.2024.2357924,
author = {Abitbol, V and Martinón-Torres, F and Taha, M-K and Nolan, T and Muzzi, A and Bambini, S and Borrow, R and Toneatto, D and Serino, L and Rappuoli, R and Pizza, M},
doi = {10.1080/21645515.2024.2357924},
journal = {Hum Vaccin Immunother},
title = {4CMenB journey to the 10-year anniversary and beyond.},
url = {http://dx.doi.org/10.1080/21645515.2024.2357924},
volume = {20},
year = {2024}
}
TY - JOUR
AB - The 4-component meningococcal serogroup B (MenB) vaccine, 4CMenB, the first broadly protective, protein-based MenB vaccine to be licensed, is now registered in more than 50 countries worldwide. Real-world evidence (RWE) from the last decade confirms its effectiveness and impact, with infant immunization programs showing vaccine effectiveness of 71-95% against invasive MenB disease and cross-protection against non-B serogroups, including a 69% decrease in serogroup W cases in 4CMenB-eligible cohorts in England. RWE from different countries also demonstrates the potential for additional moderate protection against gonorrhea in adolescents. The real-world safety profile of 4CMenB is consistent with prelicensure reports. Use of the endogenous complement human serum bactericidal antibody (enc-hSBA) assay against 110 MenB strains may enable assessment of the immunological effectiveness of multicomponent MenB vaccines in clinical trial settings. Equitable access to 4CMenB vaccination is required to better protect all age groups, including older adults, and vulnerable groups through comprehensive immunization policies.
AU - Abitbol,V
AU - Martinón-Torres,F
AU - Taha,M-K
AU - Nolan,T
AU - Muzzi,A
AU - Bambini,S
AU - Borrow,R
AU - Toneatto,D
AU - Serino,L
AU - Rappuoli,R
AU - Pizza,M
DO - 10.1080/21645515.2024.2357924
PY - 2024///
TI - 4CMenB journey to the 10-year anniversary and beyond.
T2 - Hum Vaccin Immunother
UR - http://dx.doi.org/10.1080/21645515.2024.2357924
UR - https://www.ncbi.nlm.nih.gov/pubmed/38976659
VL - 20
ER -
Interested in studying a PhD at the Department of Life Sciences? Find out more about postgraduate research opportunties.